Clostridium difficile as a biomarker (Clostridiumdifficile) · dehydrogenase and toxins

摘要

Clostridium difficile disease is associated with a range of clinical presentations, from carriers with other causes of symptoms, to mild and self-limited diarrhea, and even life-threatening pseudomembranous colon. Over to the flames and giant colon. C. Difficile cases are treated differently depending on the presence and then the severity of the disease. Patients who are carriers may not receive treatments that may cause disease. Mild to moderate cases can also be treated with metronidazole, while severe and recurrent cases are often treated with vancomycin or fidaxomycin. Current molecular assays include toxin-producing C.I. It is very sensitive to detect difficile, and the carrier status cannot be excluded. C. Utilizing a biomarker panel that includes difficile antigen (GDH), toxins A and B, and fecal lactoferrin, clinicians can use C.I. It becomes possible to distinguish between the carrier state and the active state of difficile and allows monitoring to assess the effectiveness of the treatment.